Author Archives: Santiago Gisler

β-thalassemia Patients at Risk for PAH Show Improvements on Tracleer, Case Report Says

Tracleer (bosentan) treatment improves mean pulmonary arterial pressure (mPAP) in β-thalassemia patients with potential pulmonary arterial hypertension (PAH), according to a case report of three patients. The report, “The improvement of pulmonary artery pressure after bosentan therapy in patients with β-thalassemia and Doppler-defined pulmonary arterial hypertension,”…

Morphogen-IX Announces MGX292 as Treatment Candidate for PAH

Biotechnology company Morphogen-IX recently announced that it will be further developing MGX292 as its treatment candidate for pulmonary arterial hypertension (PAH). The company’s decision is supported by previous preclinical studies that have shown the potential of MGX292, a signaling protein analogue, as a safe and effective therapy for PAH.